Ligand identification for G-protein-coupled receptors: A lead generation perspective

Current Opinion in Chemical Biology

Volumn 8, Issue 3, 2004, Pages 287-296

  Bleicher, Konrad H ^a   Green, Luke G ^a   Martin, Rainer E ^a   Rogers Evans, Mark ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

CATS; chemically advanced template search; G protein coupled receptors; GPCR; high throughput screening; HTS; nociceptin orphanin FQ receptor; OFQ; SAR; structure activity relationship

Indexed keywords

ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; BIPHENYL DERIVATIVE; CHEMOKINE RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CIPROXIFAN; G PROTEIN COUPLED RECEPTOR; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HORMONE RECEPTOR STIMULATING AGENT; LIGAND; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; OXYTOCIN ANTAGONIST; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; RECEPTOR PROTEIN; RECEPTOR SUBTYPE; THIOPERAMIDE; UNCLASSIFIED DRUG; UROTENSIN II;

ALGORITHM; BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; COMPUTER MODEL; DNA TEMPLATE; DRUG RECEPTOR BINDING; DRUG RESEARCH; HIGH THROUGHPUT SCREENING; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE; PHARMACOPHORE; PROTEIN FAMILY; PROTEIN MOTIF; PROTEIN STRUCTURE; RECEPTOR AFFINITY; REVIEW; STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; IMIDAZOLES; LIGANDS; MOLECULAR STRUCTURE; PIPERIDINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE H3; THIOUREA;

EID: 2942667923     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2004.04.008     Document Type: Review

References (63)

1. Klabunde T., Hessler G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem. 3:2002;928-944 A comprehensive review on modern strategies of drug identification of the GPCR target family.
2. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964
3. Gershengorn M.C., Osman R. Minireview: insight into G protein-coupled receptor function using molecular models. Endocrinology. 142:2001;2-10
4. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 289:2000;739-745
5. Poitout L., Roubert P., Contour-Galcéra M-O., Moinet C., Lannoy J., Pommier J., Plas P., Bigg D., Thurieau C. Identification of potent non-peptide somatostatin antagonists with SST3 selectivity. J Med Chem. 44:2001;2990-3000 An example of a successful lead identification programme capitalizing on key structural elements of the endogenous ligand.
6. 5A serotonin receptors. Bioorg Med Chem. 11:2003;717-722
7. 4 receptor ligands. Expert Opin Ther Pat. 13:2003;851-865
8. 3 receptor, having a cis-cyclopropane structure. J Med Chem. 46:2003;1980-1988
9. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology. 66:2002;128-135
10. 2A receptor. Bioorg Med Chem. 11:2003;2183-2192 Interesting work describing modifications of the endogenous ligand leading to active ligands.
11. 2B adenosine receptor. Bioorg Med Chem. 9:2001;2709-2726
12. Bräuner-Osborne H., Egebjerg J., Nielsen Eø., Madsen U., Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. J Med Chem. 43:2000;2609-2645
13. Sørensen U.S., Bleisch T.J., Kingston A.E., Wright R.A., Johnson B.G., Schoepp D.D., Ornstein P.L. Synthesis and structure-activity relationship studies of novel 2-diarylethyl substituted (2-carboxycycloprop-1-yl)glycines as high-affinity group II metabotropic glutamate receptor ligands. Bioorg Med Chem. 11:2003;197-205
14. Pin J-P., Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Current Drug Targets - CNS and Neurological Disorders. 1:2002;297-317 An excellent summary on the current knowledge of structure, physiology and ligands of the various mGlu receptor subtypes.
15. Souers A.J., Virgilio A.A., Rosenquist Å., Fenuik W., Ellman J.A. Identification of a potent heterocyclic ligand to somatostatin receptor subtype 5 by the synthesis and screening of β-turn mimetic libraries. J Am Chem Soc. 121:1999;1817-1825
16. Brenner M., Seebach D. Design, synthesis, NMR-solution and X-ray crystal structure of N-acyl-γ-dipeptide amides that form a βII′-type turn. Helv Chim Acta. 84:2001;2155-2166
17. Seebach D., Schaeffer L., Brenner M., Hoyer D. Design and synthesis of γ-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. Angew Chem Int Ed Engl. 42:2003;776-778
18. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 31:1988;2235-2246
19. Boehm H.J., Boehringer M., Bur D. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem. 43:2000;2664-2674
20. Horton D.A., Bourne G.T., Smythe M.L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev. 103:2003;893-930 A comprehensive review of the use of privileged structures in both GPCRs and non-GPCRs.
21. Patchett A.A., Nargund R.P. Privileged structures - an update. Annu Rep Med Chem. 35:2000;289-298
22. Evans B., Pipe A., Clark L., Banks M. Identification of a potent and selective oxytocin antagonist, from screening a fully encoded differential release combinatorial chemical library. Bioorg Med Chem Lett. 11:2001;1297-1300
23. 2 receptor. Drug Des Discov. 18:2002;9-21
24. Cha M.Y., Choi B.C., Kang K.H., Pae A.N., Choi K.I., Cho Y.S., Koh H.Y., Lee H-Y., Jung D., Kong J.Y. Design and synthesis of a piperazinylalkylisoxazole library for subtype selective dopamine receptor ligands. Bioorg Med Chem Lett. 12:2002;1327-1330
25. 2A receptors. Bioorg Med Chem Lett. 13:2003;175-178
26. Willoughby C.A., Hutchins S.M., Rosauer K.G., Dhar M.J., Chapman K.T., Chicchi G.G., Sadowski S., Weinberg D.H., Patel S., Malkowitz L., et al. Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. Bioorg Med Chem Lett. 12:2002;93-96
27. Palucki B.L., Feighner S.D., Pong S-S., McKee K.K., Hreniuk D.L., Tan C., Howard A.D., Van der Ploeg L.H.Y., Patchett A.A., Nargund R.P. Spiro(indoline-3, 4′-piperidine) growth hormone secretagogues as ghrelin mimetics. Bioorg Med Chem Lett. 11:2001;1955-1957
28. Bleicher K.H., Wüthrich Y., Adam G., Hoffmann T., Sleight A.J. Parallel solution- and solid-phase synthesis of spiropyrrolo-pyrroles as novel neurokinin receptor ligands. Bioorg Med Chem Lett. 12:2002;3073-3076
29. Bleicher K.H., Wüthrich Y., De Boni M., Kolczewski S., Hoffmann T., Sleight A.J. Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands. Bioorg Med Chem Lett. 12:2002;2519-2522
30. Hajduk P.J., Bures M., Praestgaard J., Fesik S.W. Privileged molecules for protein binding identified from NMR-based screening. J Med Chem. 43:2000;3443-3447
31. 3 prostanoid receptor. Bioorg Med Chem Lett. 12:2002;2583-2586
32. 2-receptor antagonists. Bioorg Med Chem Lett. 12:2002;2065-2068
33. Jacoby E. Biphenyls as potential mimetics of protein α-helix. Bioorg Med Chem Lett. 12:2002;891-893 A theoretical examination of the origin of the privileged nature of the biphenyl motif.
34. Jacoby E. A novel chemogenomics knowledge-based ligand design strategy - Application to G protein-coupled receptors. Quant Struct-Act Relat. 20:2001;115-123
35. Perlman J.H., Colson A-O., Jain R., Czyzewski B., Cohen L.A., Osman R., Gershengorn M.C. Role of the extracellular loops of the thyrotropin-releasing hormone receptor: Evidence for an initial interaction with thyrotropin-releasing hormone. Biochemistry. 36:1997;15670-15676
36. 1 receptor. Biochemistry. 38:1999;3498-3507
37. Derian C.K., Maryanoff B.E., Andrade-Gordon P., Zhang H-C. Design and evaluation of potent peptide-mimetic PAR1 antagonists. Drug Dev Res. 59:2003;355-366 A fascinating case study of the combined use of ligand and target information to formulate a de novo lead.
38. Chianelli D., Kim Y-C., Lvovskiy D., Webb T.R. Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: Synthesis of ligands for somatostatin receptors. Bioorg Med Chem. 11:2003;5059-5068 The employment of an algorithm representing β-turns to design new leads from an in-house scaffold.
39. 3 receptor antagonists, using the newly developed molecular modeling program SLATE. J Med Chem. 44:2001;1666-1674
40. 3 receptor explaining agonistic and antagonistic activity simultaneously. Arch Pharm. 333:2000;254-260
41. Mills J.E.J., de Esch I.J.P., Perkins T.D.J., Dean P.M. SLATE: A method for the superimposition of flexible ligands. J Comput Aided Mol Des. 15:2001;81-96 The introduction of a program for the superimposition of a pair of flexible molecules according to their hydrogen-bonding properties, aromatic rings and other user-defined atoms and its application to drug design for H3 antagonists.
42. Böhm H-J, Schneider G: Virtual screening for bioactive molecules. Weinheim: Wiley-VCH;2000.
43. Walters W.P., Stahl M.T., Murcko M.A. Virtual screening - an overview. Drug Discov Today. 2:1998;160-178
44. Chen Z., Miller W.S., Shan S., Valenzano K.J. Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor. Bioorg Med Chem Lett. 13:2003;3247-3252
45. Schneider G., Neidhart W., Adam G. Integrating virtual screening methods to the quest for novel membrane protein ligands. Curr Med Chem. 1:2001;99-112 This paper demonstrates the first successful application of 2D-topological similarity searching for the discovery of novel GPCR ligands.
46. 2a) antagonists using self-organizing maps. J Comb Chem. 5:2003;233-237
47. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 1:2002;882-894
48. Mason J.S., Good A.C., Martin E.J. 3-D pharmacophores in drug discovery. Curr Pharm Des. 7:2001;567-597
49. Huang P., Loew G.H., Funamizu H., Mimura M., Ishiyama N., Hayashida M., Okuno T., Shimada O., Okuyama A., Ikegami S., et al. Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. J Med Chem. 44:2001;4082-4091
50. Rohrer S.P., Birzin E.T., Mosley R.T., Berk S.C., Hutchins S.M., Shen D-M., Xiong Y., Hayes E.C., Parmar R.M., Foor F., et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 282:1998;737-740
51. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem. 45:2002;1799-1805
52. 3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J Med Chem. 46:2003;4377-4392
53. Bissantz C., Bernard P., Hibert M., Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins. 50:2003;5-25 The application of homology models to virtual screening is described. Although a simple homology model was suitable for finding antagonists, refinement of the model with known agonists was required before it could be used for agonist screening.
54. Evers A., Klebe G. Ligand-supported homology modeling of G-protein-coupled receptor sites: models sufficient for successful virtual screening. Angew Chem Int Ed Engl. 43:2004;248-251 A system for the development of a more accurate homology model by using interactions with known ligands to refine the initially generated model and its application to the NK1 receptor.
55. Lloyd D.G., Buenemann C.L., Todorov N.P., Manallack D.T., Dean P.M. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J Med Chem. 47:2004;493-496
56. Schneider G., Clément-Chomienne O., Hilfiger L., Schneider P., Kirsch S., Böhm H-J., Neidhart W. Virtual screening for bioactive molecules by evolutionary de novo design. Angew Chem Int Ed Engl. 39:2000;4130-4133
57. Rose S., Stevens A. Computational design strategies for combinatorial libraries. Curr Opin Chem Biol. 7:2003;331-339
58. 2) agonists. J Med Chem. 41:1998;2175-2179
59. Elliott J.M., Cascieri M.A., Chicchi G., Davies S., Kelleher F.J., Kurtz M., Ladduwahetty T., Lewis R.T., MacLeod A.M., Merchant K.J., et al. Serine derived NK1 antagonists 1: the effect of modifications to the serine substituents. Bioorg Med Chem Lett. 8:1998;1845-1850
60. Kolczewski S., Adam G., Cesura A.M., Jenck F., Hennig M., Oberhauser T., Poli S.M., Roessler F., Roever S., Wichmann J., Dautzenberg F.M. Novel hexahydrospiro[piperidine-4, 1'-pyrrolo[3, 4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists. J Med Chem. 46:2003;255-264
61. Mirzadegan T., Diehl F., Ebi B., Bhakta S., Polsky I., McCarley D., Mulkins M., Weatherhead G.S., Lapierre J-M., Dankwardt J., et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J Biol Chem. 275:2000;25562-25571
62. Makovec F., Peris W., Revel L., Giovanetti R., Mennuni L., Rovati L.C. Structure-antigastrin activity relationships of new (R)-benzamido-5-oxopentanoic acid derivatives. J Med Chem. 35:1992;28-38
63. Nargund R.P., Barakat K.H., Cheng K., Chan W.W.S., Butler B.R., Patchett A.A. Synthesis and biological activity of camphor-based non-peptide growth hormone secretagogues. Bioorg Med Chem Lett. 6:1996;1265-1270